130.00
—
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sotac Pharmaceuticals
Its shares trade on NSE under the ticker SOTAC.NS. It has been listed since 13 April 2023. In the fiscal year to 31 March 2025, it reported revenue of ₹969.9m and net income of ₹80.3m. At that date it held total assets of ₹1.24bn and shareholders' equity of ₹532.5m.
Sotac Pharmaceuticals Ltd. engages in developing and manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-04-13. The firm specializes in the manufacturing of a range of pharmaceutical products, such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-Lactam syrup, and external preparations. The company is engaged in the business of manufacturing pharmaceutical products for different marketers on a loan license or contract manufacturing basis. Its therapeutic portfolio includes Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, AntiAllergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, AntiPyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin. Its subsidiaries include SOTAC Healthcare Private Limited (SOTAC Healthcare), SOTAC Research Private Limited (SOTAC Research), and SOTAC Lifescience Private Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Apr 2023
- Employees
- 89
- Website
- sotacpharma.com/contact-us ↗
Leadership
Pay as last reported
- Mr. Sharadkumar PatelManaging Director, Executive Chairman, since 2022₹1.8m
- Mr. Brijeshkumar PatelChief Financial Officer₹490,000
- Mr. Pankaj MahabaleshwarkarChief Operating Officer
- Ms. Niyati ParikhChief Compliance Officer, Company Secretary
- Mr. Dineshkumar GelotWhole Time Director, since 2022₹1.8m
- Mr. Chetankumar PatelExecutive Director, since 2022
- Mr. Vishalkumar PatelExecutive Director, since 2022
- Mr. Bhavinkumar JoshiAdditional Independent Non-Executive Director
- Mr. Ketankumar ModiIndependent Non-Executive Additional Director
- Ms. Dimpal PatelAdditional Independent Non-Executive Director
- Mrs. Heena PatelNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sotac Pharmaceuticals Ltd specializes in Non Beta-Lactam tablets and capsules manufacturing in Ahmedabad.
- Sotac Healthcare Private Limited supports contract manufacturing for Anti-Diabetic and Anti-Psychotic products.
- SOTAC Research Private Limited focuses on developing new pharmaceutical formulations for Anti-Cold and Anti-Allergic markets.
Weaknesses
- Sotac Pharmaceuticals has 89 employees which is a small workforce for a pharmaceutical manufacturer.
- The company's IPO on April 13, 2023, indicates limited market presence.
- Sotac Lifescience Private Limited lacks detailed product portfolio information.
Opportunities
- Sotac Pharmaceuticals can expand its manufacturing of Anti-Ulcerants and PPI products in the Indian market.
- The growing demand for Anti-Hypertensives in India presents a significant opportunity.
- SOTAC Research Private Limited can leverage new formulations for Anti-Bacterial and Anti-Viral markets.
Threats
- Sotac Pharmaceuticals faces competition from established Indian pharmaceutical companies in the Anti-Diabetic segment.
- The Indian pharmaceutical market is highly competitive with many contract manufacturers.
- Regulatory changes in the Indian Health Care sector could impact manufacturing operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.